Rohto PharmaceuticalROHTO PHARMACEUTICAL CO.,LTD.4527東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥12 is left as operating profit. Revenue changed +11.4% from the prior year, operating profit +7.5%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 10.6% | 0.73× | 7.7% | 1.62× | 12.5% |
| 2023 | 11.1% | 0.82× | 9.0% | 1.62× | 14.6% |
| 2024 | 11.4% | 0.83× | 9.4% | 1.61× | 15.2% |
| 2025 | 10.0% | 0.79× | 7.9% | 1.76× | 13.9% |
| 2026 | 10.0% | 0.74× | 7.4% | 1.92× | 14.2% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 199,646 | 238,664 | 270,840 | 308,625 | 343,725 |
| Cost of revenue | 83,476 | 101,243 | 113,554 | 134,232 | 151,030 |
| Gross profit | 116,170 | 137,421 | 157,285 | 174,393 | 192,695 |
| SG&A | 87,154 | 103,461 | 117,237 | 136,158 | 151,576 |
| Operating income | 29,015 | 33,959 | 40,048 | 38,234 | 41,118 |
| Pretax income | 27,874 | 34,290 | 41,518 | 41,626 | 46,821 |
| Income tax | 6,686 | 7,860 | 10,123 | 11,164 | 12,404 |
| Net income attributable to owners | 21,127 | 26,377 | 30,936 | 30,841 | 34,247 |
| Operating margin | 14.5% | 14.2% | 14.8% | 12.4% | 12.0% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥70.9B | ¥77.7B | ¥86.6B | ¥73.2B | ¥82.9B |
| Total assets | ¥274.9B | ¥309.7B | ¥346.2B | ¥437B | ¥485.8B |
| Net assets | ¥184B | ¥215.1B | ¥247B | ¥280.7B | ¥320.2B |
| Share capital | ¥6.5B | ¥6.5B | ¥6.5B | ¥6.5B | ¥6.5B |
| Trade receivables | ¥33.3B | ¥39.7B | ¥44.7B | ¥47.1B | ¥52.7B |
| Property, plant and equipment | ¥62.8B | ¥66.2B | ¥68.6B | ¥90.5B | ¥93B |
| Intangible assets excluding goodwill | ¥9.54B | ¥9.56B | ¥9.22B | ¥71.2B | ¥83.9B |
| Goodwill | ¥2.95B | ¥2.56B | ¥2.29B | ¥34.8B | ¥34.2B |
| Investment securities | ¥28.1B | ¥33.6B | ¥44.3B | ¥46.4B | ¥55.9B |
| Current assets | ¥164.3B | ¥190.2B | ¥214.8B | ¥217.9B | ¥239.3B |
| Current liabilities | ¥71.5B | ¥80.2B | ¥87.1B | ¥94.6B | ¥117.3B |
| Trade payables | ¥13.7B | ¥16B | ¥17B | ¥19.1B | ¥20.9B |
| Short-term borrowings | ¥8.03B | ¥4.18B | ¥5.3B | ¥7.04B | ¥24.7B |
| Long-term borrowings | ¥13.3B | ¥7.52B | ¥5.19B | ¥17.8B | ¥2.87B |
| Total liabilities | ¥90.9B | ¥94.6B | ¥99.1B | ¥156.3B | ¥165.6B |
| Non-controlling interests | ¥5.59B | ¥5.51B | ¥710M | ¥17.4B | ¥18.3B |
| Equity attributable to owners of parent | ¥169.7B | ¥190.9B | ¥215.5B | ¥228.3B | ¥253.2B |
| Retained earnings | ¥162.3B | ¥184B | ¥209.4B | ¥231.7B | ¥256.6B |
| Treasury stock | -¥4.94B | -¥4.94B | -¥4.94B | -¥9.94B | -¥9.94B |
EDINET (FSA Japan)
有価証券報告書－第90期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第89期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第88期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第87期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第86期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第85期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 56 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.